Career Possibilities: Research & Development/Application - AI, Digital Health, Devices

Download the event flyer

See other events in this series:

10/8: Career Possibilities: Research & Development - Biotech, Pharma, Medical

12/5: Career Possibilities: Business Development/Alliance Management/Innovation/Licensing

Dr. Anna Barnacka is the founder and CEO of MindMics, Inc. MindMics has invented a breakthrough in precision monitoring for precision medicine. Anna finished her NASA Einstein Fellowship at Harvard in 2018 and transitioned from astrophysics to startups. She has a broad experience in signal processing, data analysis, and modeling, software development, as well as, building infrastructures and instrumentations for systems requiring rocket science and cosmic precision.

Under Annabella Jucius’ leadership, Massachusetts Medical Consulting was founded to provide exceptional clinical research consulting in the areas of project management, monitoring, and medical writing. An accomplished project manager with extensive clinical experience in the medical device industry, Annabella has been recognized for her exceptional collaboration and leadership skills, cross-functional team development, and her innovative problem-solving attitude. Annabella received her Bachelor of Science in Biotechnology from the Worcester Polytechnic Institute and completed the Greater Boston Executive Program from the Massachusetts Institute of Technology. 

Mary Ann O’Loughlin having recently retired from Harvard Business School (HBS) Mary Ann now brings her advisory expertise to global executives as a both a business consultant and leadership coach. Her business career has spanned sales, marketing, consulting, and senior management roles in large corporations and small start-ups. Prior to joining HBS in 2007, Mary Ann spent ten years with the UK research and consulting company Ovum in both London and Boston. In addition to her own work as a telecoms sector Principal Consultant, she managed Ovum’s US operation as President of Ovum North America for five years. Previously, Mary Ann had founded and managed a consulting and telecoms service company in France and, earlier in her career, she worked for IBM Canada, Hewlett Packard and Alcatel in senior sales and product marketing positions. Mary Ann holds a BS in Physics from McMaster University (Ontario), an MS in Biophysics from the University of Toronto, an MBA from Insead, and a graduate certificate in Executive Coaching from the William James College. 

Virginia Parks has over 20 years of global drug development experience across multiple therapeutic areas including neuroscience, cardiovascular, metabolic disorders, and rare diseases. She is currently a digital strategy lead with Takeda in their Data Science Institute. Prior to this she was a Clinical Pharmacology Lead at Shire. She brought her broad experience in drug development and cross-functional leadership to this role and was a key member of early phase clinical development teams with an accent on innovation. This included identification of wearable technology, analytics development and validation, patient engagement, and use of external data sources. Prior to joining Shire, Virginia worked for Pfizer and Wyeth where she was primarily focused on leading early stage exploratory programs. She received her master’s degree in neuroscience from Kings College London, UK, and has been awarded post-graduate training awards in Clinical Pharmacology.

Dr. Birgit Schoeberl joined NIBR at the beginning of  2018 as Global Head of Modeling and Simulation, PK Sciences at Novartis. Before joining Novartis, Birgit served as interim Senior Vice President, Scientific Value, at GNS Healthcare. During her time at GNS, she focused on applying causal machine learning  to drug development. Prior to GNS, she was a member of the founding team at Merrimack Pharmaceuticals and where she spent over 12 years in different roles. In her latest role as Head of Discovery and Early Development, she gained broad experience in oncology drug discovery and development. Birgit and her leadership team were responsible for multiple preclinical and early clinical programs. Birgit received her Chemical Engineering degree from the Technical University in Karlsruhe, Germany, and her Ph.D. in Biological Engineering from the Max Planck Institute for Dynamics of Complex Technical Systems in Magdeburg. She was a post-doctoral fellow in the laboratories of Douglas Lauffenburger and Peter Sorger in the Biological Engineering Department at MIT.